Genetic Variations in TXNRD1 as Potential Predictors of Drug-Induced Liver Injury by Kwon, Jae-Woo et al.
132 © Copyright The Korean Academy of Asthma, Allergy and Clinical Immunology • The Korean Academy of Pediatric Allergy and Respiratory Disease http://e-aair.org
INTRODUCTION
Drug-induced liver injury (DILI) is an unpredictable adverse 
drug reaction that affects only a small subset of treated patients. 
As a result, DILI is scarcely detected during pre-approval clini-
cal trials, and therefore remains the single leading cause of drug 
withdrawal from the market.
1 Liver injury has been linked to 
nearly 1,000 drugs and DILI is the most common cause of acute 
liver failure in the US, where it accounts for more than half of all 
acute liver failures.
2,3 The mechanism underlying DILI is thought 
to be two-staged and likely involves non-immune and immune-
mediated stages. Liver injury is initiated by the direct hepato-
toxic effects of a drug or its reactive metabolites, and subse-
quently, the resulting parenchymal cell injury induces activa-
tion of innate and/or adaptive immune cells. This immune cell 
activation in turn produces proinflammatory and hepatotoxic 
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mediators and initiates immune reactions against drug-associ-
ated antigens.
1,4 Many studies suggest that DILI results from the 
production of reactive metabolites that accumulate within he-
patocytes at levels that exceed some critical threshold.
1,5,6
We hypothesized that there could be a common susceptibility 
gene for DILI that acts during the initiative non-immune-medi-
ated stage. Based on the results of a microarray analysis from 
previous studies on toxic hepatitis in animal models,
7,8 we se-
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Purpose:  Drug-induced liver injury (DILI) is the most common adverse drug reaction; however, it is not easily predicted. We hypothesize that DILI 
has a common genetic basis. Based on the findings of previous animal studies on toxic hepatitis, we selected the thioredoxin reductase 1 gene 
(TXNRD1) as a candidate marker of DILI for this genetic association study.  Methods:  Records from 118 patients with DILI were extracted from the 
database of the Adverse Drug Reaction Research Group in South Korea. Causative drugs included antituberculosis drugs (n=68, 57.6%), antibiotics 
(n=22, 18.6%), antiepileptic drugs (n=7, 5.9%), non-steroidal anti-inflammatory drugs (n=5, 4.2%), and others (n=16, 13.7%). Seven single nucle-
otide polymorphisms (SNPs) in TXNRD1 (rs10735393, rs4964287, rs4595619, rs10861201, rs11111997, rs4246270, and rs4246271) were scored in 
118 DILI patients and in 120 drug-matched controls without liver injury.  Results:  No differences were found between the frequencies of any of the 
7 SNPs in the cases and controls; however, a significant association was found between a TTA haplotype composed of rs10735393, rs4964287, and 
rs4595619 and DILI using an allele model (odds ratio, 1.79; 95% confidence interval, 1.18-2.73; P=0.008; Bonferroni corrected P=0.024).  Conclu-
sions:  These results suggest that genetic variations in TXNRD1 favor the development of DILI, although a larger confirmative study is needed.
Key Words:  Drug-induced liver injury; genetic association study; genetic polymorphism; single nucleotide polymorphisms; thioredoxin reductase 1
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lected the thioredoxin reductase 1 gene (TXNRD1) as a poten-
tial marker of DILI and performed this genetic association study. 
TXNRD1 has been found to be commonly dysregulated in pre-
vious studies using DNA microarray analyses of toxic hepatitis 
induced by various compounds in animal models.
7,8 TXNRD1 
is a NADPH-dependent enzyme and is known to be related to 
oxidative stress and the regulation of cell growth and transfor-
mation.
 
MATERIALS AND METHODS
Study subjects and phenotype definitions
Records from 118 patients with DILI were extracted from the 
database of the Adverse Drug Reaction Research Group in Ko-
rea, members of which are drawn from 6 tertiary hospitals (Seoul 
National University Hospital, Hanyang University Hospital, 
Ajou University Hospital, Dankook University Hospital, Seoul 
National University Bundang Hospital, and Eulji University 
Hospital). DILI was defined as drug-induced acute hepatocel-
lular injury with an aspartate aminotransferase level≥upper 
limit of normal (ULN) and an (aspartate aminotransferase/
ULN)/(alkaline phosphatase/ULN) ratio≥5.
10 No patients show-
ed any other organ involvement other than liver involvement, 
except peripheral eosinophilia. The time between the initiation 
of the causative drug and symptom onset was ≤14 days. Cau-
sality between hepatitis and each drug was assessed using the 
Naranjo algorithm, which is used to assess the likelihood that a 
change in clinical status is the result of an adverse drug reaction 
rather than the result of other factors such as the progression of 
an underlying disease. The Naranjo algorithm uses a scoring 
system that is related to the possibility of underlying disease ex-
acerbation, previous reports of drug adverse reaction, timing of 
onset, results of de-challenge or re-challenge, and any objective 
evidence of drug adverse reaction.
11,12 One hundred and twenty 
drug-matched controls were recruited from the above-men-
tioned hospitals. All control patients had been prescribed the 
same drugs but had not developed liver injury. All subjects en-
rolled in this study provided written informed consent, and the 
study protocol was approved by the Institutional Review Boards 
at each of the above-mentioned hospitals.
Gene and single nucleotide polymorphism selection and 
genotyping
After reviewing the results of previous microarray analysis 
studies conducted on toxic hepatitis animal models, we select-
ed TXNRD1 as a candidate gene.
7,8 Based on Japanese data in 
HapMap (Japanese genetic constitutions are similar to those of 
Koreans), 7 tagging SNPs (rs10735393, rs4964287, rs4595619, 
rs10861201, rs11111997, rs4246270, and rs4246271) on TXNRD1 
(minor allele frequency≥5% and linkage disequilibrium coeffi-
cient r
2≥0.8) were selected (Table 1; Figure). Haplotypes and 
their frequencies were estimated using an expectation–maxi-
mization algorithm using Haploview 3.32 (available online at 
http://www.broad.mit.edu/mpg/haploview). Inferred haplo-
type blocks are shown in Figure. Scoring was performed using 
the high-throughput single base-pair extension method (SNP-
ITTM assay) with an SNPstream25K system customized to au-
tomatically genotype DNA samples in 384-well plates, and to 
provide a colorimetric readout (Orchid Biosciences, Princeton, 
NJ, USA), as described previously.
13
Statistical analysis
An association analysis was performed for each SNP using an 
allelic model (A versus B, where A is the major allele and B the 
minor allele [for haplotype analysis, a haplotype vs. the other 
haplotypes]), which assessed the elevated risk of disease devel-
opment in individuals carrying a risk allele (or haplotype). P 
values and odds ratios (ORs) were determined by logistic re-
gression analysis and controlled for age and sex. Compliance 
with Hardy-Weinberg equilibrium was determined using 2×2 
tests. All statistical analyses were performed using SAS 9.1 soft-
ware (SAS Institute Inc., Cary, NC, USA), and P<0.05 was re-
garded as statistically significant.
RESULTS
The mean age of the 118 cases was 46.9±18.3 years (mean±
standard deviation [SD]) and 72 (61.0%) were male (Table 2). 
The mean age of the 120 controls was 49.8±11.3 years (mean±
SD) and 95 (79.1%) were male. Neither age nor sex was signifi-
cantly different in cases and controls. Causative drugs were an-
tituberculosis drugs (n=68, 57.6%), antibiotics (n=22, 18.6%), 
antiepileptic drugs (n=7, 5.9%), non-steroidal anti-inflamma-
tory drugs (n=5, 4.2%), and others (n=16, 13.7%).
We failed to find differences between the frequencies of any of 
the 7 SNPs in the cases and controls after Bonferroni correction 
(Table 3). However, we did find a significant association be-
tween the TTA haplotype (composed of rs10735393, rs4964287, 
and rs4595619) and DILI using an allele model (OR, 1.79; 95% 
confidence interval, 1.18-2.73; P=0.008; Bonferroni corrected 
Table 1. SNPs of TXNRD1 evaluated in this study
SNP ID
Allele Minor allele 
frequency* Major Minor
rs10735393 T G 0.2009
rs4964287 C T 0.2188
rs4595619 G A 0.4188
rs10861201 C A 0.0042
rs11111997 T C 0.1197
rs4246270 A G 0.1752
rs4246271 G C 0.1780
*In the control group.
SNP, single nucleotide polymorphism.Kwon et al.
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P=0.024).
DISCUSSION
Two major mechanisms have been proposed to be responsi-
ble for DILI: the intrinsic hepatotoxicity of a particular drug or 
its metabolites and an immune-mediated reaction leading to 
Table 2. Characteristics of DILI patients (n=118)
Characteristics Number (%)
Age, mean (±SD) 47.0 (±18.3) yr
Male 72 (61.0%)
Causative drugs
Antituberculosis drugs 68 (57.6%)
Antibiotics 22 (18.6%)
Antiepileptic drugs 7 (5.9%)
Non-steroidal anti-inflammatory drugs 5 (4.2%)
Others 16 (13.7%)
Liver function test, mean (±SD)
Aspartate aminotransferase (IU/mL) 1114.3 (±9,294.7)
Alanine aminotransferase (IU/mL) 319.23 (±387.5)
Accompanying symptoms
Exanthematous skin lesion 29 (24.6%)
Peripheral eosinophilia 23 (19.5%)
Hemolytic anemia 2 (1.7%)
Leukopenia 2 (1.7%)
Thrombocytopenia 2 (1.7%)
DILI, drug-induced liver injury.
Table 3. Individual SNPs (allele model)
SNP P value* OR (95% CI)
rs10735393 0.079 0.64 (0.38-1.54)
rs4964287 0.116 5.68 (0.65-49.94)
rs4595619 0.183 1.43 (0.84-2.45)
rs10861201 0.056 0.59 (0.34-1.01)
rs11111997 0.047 0.58 (0.34-0.99)
rs4246270 0.324 1.20 (0.83-1.76)
rs4246271 0.027 1.63 (1.05-2.51)
*After Bonferroni correction (multiplied by 7), no SNP showed a significant as-
sociation with the presence of DILI.
SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; 
DILI, drug-induced liver injury.
Figure. Gene map of thioredoxin reductase 1 (TXNRD1) and inferred haplotype blocks. (A) Schematic gene map and single nucleotide polymorphisms (SNPs) in 
TXNRD1 on chromosome 12q23-q24.1. Black blocks represent coding exons and white blocks represent 5’ and 3’UTR. (B) Inferred haplotype blocks with LD coeffi-
cients (|D’| and r
2) among SNPs. (C) Distributions of major haplotypes in block 1.
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hepatic inflammation and injury. Nevertheless, DILI is suspect-
ed to be initiated by liver damage in both mechanisms, which 
compromises the immunologically privileged status of the liv-
er.
14 As an example of a complex-trait disease, many genetic 
variants have been found for DILI that are associated with vari-
ous processes, such as bioactivation/transport pathways, de-
toxifying enzymes, and transporters.
15-20 Most of these genetic 
variants suggest that DILI results from the production of reac-
tive metabolites that accumulate within hepatocytes to levels 
that exceed certain critical thresholds. This reactive metabolite 
hypothesis could explain individual susceptibilities to DILI re-
lated to genotype, poor metabolism, or a reduced capacity to 
resist or recover from injury.
5,6 Furthermore, because liver dam-
age is a common initial step of DILI caused by different drugs, 
there could be a common genetic basis to DILI susceptibility.
TXNRD1 is a NADPH-dependent enzyme that catalyzes the 
reduction of thioredoxin.
9 TXNRD1 is known to play a role in 
cell growth and transformation and to protect cells against inju-
ry by oxidants. In a previous DNA microarray analysis of toxic 
hepatitis in animals (induced by several different hepatotoxic 
compounds), TXNRD1 was found to be commonly dysregulat-
ed under conditions of acute hepatotoxicity.
7,8 Minami et al.
7 
sought to determine whether a relationship exists between the 
gene expression profiles and hepatotoxic phenotypes of 5 hep-
atotoxic chemicals in rats (acetaminophen, bromobenzene, 
carbon tetrachloride, dimethylnitrosamine, and thioacetamide), 
and found that TXNRD1 was upregulated in rats treated with 
these chemicals. Similarly, the expression of TXNRD1 was ele-
vated in liver tissues after treatment with 6 hepatotoxic com-
pounds (tetracycline, carbon tetrachloride, 1-naphthylisothio-
cyanate, erythromycin estolate, acetaminophen, or chloro-
form), but not after administration of non-hepatotoxic com-
pounds.
8 TXNRD1 is an enzyme with broad substrate specifici-
ty related to oxidant challenge, and thus, seems to be a good 
candidate common marker of DILI. However, despite recent 
enthusiasm, it seems that genetic variations in TXNRD1 do not 
entirely explain DILI. As has been suggested by other investiga-
tors, DILI appears to be caused by a combination of several ge-
netic variations rather than a single mutation.
16 Nevertheless, 
our results encourage us to consider that common genetic vari-
ations contribute to DILI development by various drugs.
Among the seven targeted SNPs, rs10735393 is located in the 
promoter region, rs4964287 is a synonymous SNP in the coding 
region, and the other SNPs are located in the intron region. There 
have been no functional studies related to these seven SNPs. 
However, as mentioned above, TXNRD1 has been found to be 
commonly dysregulated in previous studies using DNA micro-
array analyses in animal models of toxic hepatitis induced by 
various compounds.
7,8
Several important limitations of the present study should be 
mentioned. First, different causative drugs related to DILI were 
examined in this study; therefore, the study population for each 
drug was too small to establish a common pathway for DILI. 
Second, the cases enrolled in the present study had comorbidi-
ties in addition to DILI, and this could have acted as a confound-
ing factor. However, a variety of comorbidities and comparisons 
with healthy controls might dilute these confounding effects. In 
addition, the comparability of the case and control subjects was 
not fully investigated because the definition of control subjects 
totally depended on self-reported questionnaires. Furthermore, 
we could not completely remove the risk that spurious interac-
tions might have been identified due to the relatively small size 
of the study population. Accordingly, we suggest that our re-
sults be confirmed by a larger study.
In summary, the present study shows that genetic variations 
in TXNRD1 significantly increase the likelihood of DILI. Al-
though DILI is a rare and complex-trait disease, we believe that 
genetic variations in TXNRD1 could be a common marker of 
susceptibility for DILI by various drugs, although a larger con-
firmative study is needed.
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